NCT07102381Phase 2Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-01-01Estimated

Enrollment · participants125Estimated

Source updated2026-08-25Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-07 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

HER2-positive Breast Cancer; Breast Cancer

Treatments or interventions studied

ZanidatamabDrugAlso known as ZW25, JZP598, ZIIHERA®
PaclitaxelDrug
DocetaxelDrug
CarboplatinDrug
TrastuzumabDrug
PertuzumabDrug

Primary outcomes · main study measures

measure: Number of participants with pCR; description: Pathologic complete response (pCR) is defined as lacking all signs of cancer in the tissue samples removed in the breast or axilla (armpit) during surgery or biopsy after study treatment; timeFrame: Up to 8 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history